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Abstract
Background: Histone methylation is thought to be central to the epigenetic mechanisms that
maintain and confine cellular identity in multi-cellular organisms. To examine epigenetic roles in
cellular homeostasis, we conditionally mutated the histone 3 lysine 4 methyltransferase, Mll2, in
embryonic stem (ES) cells, during development and in adult mice using tamoxifen-induced Cre
recombination.
Results: In ES cells, expression profiling unexpectedly revealed that only one gene, Magoh2, is
dependent upon Mll2 and few other genes were affected. Loss of Mll2 caused loss of H3K4me3 at
the Magoh2 promoter and concomitant gain of H3K27me3 and DNA methylation. Hence Mll2,
which is orthologous to Drosophila Trithorax, is required to prevent Polycomb-Group repression
of the Magoh2 promoter, and repression is further accompanied by DNA methylation. Early loss
of Mll2 in utero recapitulated the embryonic lethality found in Mll2-/- embryos. However, loss of
Mll2 after E11.5 produced mice without notable pathologies. Hence Mll2 is not required for late
development, stem cells or homeostasis in somatic cell types. However it is required in the germ
cell lineage. Spermatogenesis was lost upon removal of Mll2, although spermatogonia A persisted.
Conclusion: These data suggest a bimodal recruit and maintain model whereby Mll2 is required
to establish certain epigenetic decisions during differentiation, which are then maintained by
redundant mechanisms. We also suggest that these mechanisms relate to the epigenetic
maintenance of CpG island promoters.
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Epigenetic mechanisms play several roles in genome func-
tion including the maintenance of genome stability, sup-
pression of transposons, dosage compensation and
imprinting, as well as the regulation of gene expression.
Despite much progress, the understanding of gene regula-
tion by epigenetic mechanisms remains far from com-
plete. For example, epigenetic mechanisms contribute to
the differences in gene expression patterns between
somatic cells, and to the loss of pluripotency during devel-
opment [1-4]. However, it is still not understood whether
these mechanisms direct decisions during lineage com-
mitment and differentiation, or merely secure them.
Amongst the several classes of histone post-translational
modifications, the six lysine methylations on histones 3
and 4 have emerged as central to epigenetic mechanisms,
with each apparently relating to a different chromatin sta-
tus [3]. In mammals, unraveling epigenetic roles in gene
expression is likely to prove difficult. Even assuming that
epigenetic mechanisms are largely confined to DNA and
histone methylation, the existence of multiple enzymes
for each modification complicates the analysis. For exam-
ple, by bioinformatic criteria, there are at least six H3K4
and seven H3K9 methyltransferases amongst more than
42 candidate enzymes [5]. Of these, at least half appear to
be pairs of sister genes, indicating that redundancy may
obscure studies to determine their functional roles. Never-
theless, knock-outs of six of the nine histone methyltrans-
ferases studied so far are embryonic lethal in the mouse
[5-12].
The studies reported here began with the aim to explore
and compare epigenetic functions in pluripotent and
somatic cells. We reasoned that epigenetic mechanisms
secure a particular cellular state by maintaining a charac-
teristic gene expression pattern. Thereby a single genome
can be reliably utilized in many different ways because
epigenetic modifications fix the different gene expression
patterns that define different cellular states [2-4,13]. Con-
sequently a role for epigenetics in cellular homeostasis is
implied.
To explore these issues, we chose the H3K4 methyltrans-
ferase Mll2/Wbp7 (Figure 1A), which is the sister of Mll
(mixed lineage leukemia) by gene duplication [14]. Both
Mll and Mll2 are widely expressed throughout develop-
ment and in adults and both are required for embryogen-
esis, however show different phenotypes when knocked-
out [5,7,12]. Hence exploration of their cellular and
somatic roles requires a strategy for conditional mutagen-
esis. We used ligand-regulated site-specific recombination
[15] mediated by Cre recombinase-mutant estrogen
receptor fusion proteins (Cre-ERT) to induce loss of Mll2.
We aimed at temporal recombination without spatial
Conditional Mutagenesis of Mll2Figure 1
Conditional Mutagenesis of Mll2. (A) Scheme of the Mll2 
protein, which contains several domains and motifs including 
AT hooks; SNLs (speckled nuclear localization sequences); 
the CxxC DNA binding region; three PHD fingers and an 
extended PHD finger (ePHD); a sequence similar to a Bromo 
domain; the FYR-N and -C domains (which dimerize); a 
transactivation domain (TD); a cleavage site (CS) for Taspase; 
and the SET domain, which is the H3K4 methyltransferase 
domain. (B) Scheme of the strategy for conditional mutagen-
esis. The CreERT2 protein was ubiquitously expressed from 
the Rosa26 locus but repressed by the Hsp90 complex. 
Tamoxifen binding releases CreERT2 from Hsp90 to permit 
Cre recombination of the loxP sites surrounding exon 2 of 
Mll2, which causes a frame-shift mutation. (C) A Southern 
blot to determine recombination efficiency in Mll2F/F; 
Rosa26-CreERT2/+ ES cells at various timepoints (0 to 96 
hours) after addition of 4-hydroxy tamoxifen. (D) The same 
time course as shown in (C) was evaluated for Mll2 protein 
levels by western blotting. Wild type (wt) and Mll2-/- ES cells 
served as controls. (E) Summary of microarray expression 
profiling from Mll2-/- (constitutive) cells compared with wt or 
FLP rescued cells and tamoxifen-treated (conditional) com-
pared with untreated mll2F/F; Rosa26-CreERT2/+ cells. At the 
left, the summary shows the number of genes whose mRNA 
expression level increased or decreased at least 1.7-fold in 
either the constitutive or conditional experiment. At the 
right, the overlap between the down-regulated genes in the 
two experiments is shown, along with the number of CpG 
island promoters in the three categories.
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Epigenetics & Chromatin 2009, 2:5 http://www.epigeneticsandchromatin.com/content/2/1/5restrictions by using a Cre-ERT2 transgene [16] targeted to
the ubiquitous Rosa26 locus [17]. Thereby functional
enquiry can be directed towards any cell at a chosen time,
which is a prerequisite for the study of homeostasis.
Results
Tamoxifen induces complete loss of Mll2
Using a multi-purpose 'knock-out first' allele [18] for
Mll2, we previously found that Mll2 null embryos die
before E10.5 [5]. To assess Mll2 function in embryonic
stem (ES) cells, after E10.5 and in adult mice, we con-
verted the knock-out allele into a conditional one by
FLPe-mediated removal of the stop cassette [19]. The con-
ditional allele (termed 'F' for FLP recombined) includes
loxP sites flanking the 73 bp second exon. Removal of
exon 2 by Cre recombination invokes a frame shift in the
mRNA resulting in a premature stop codon and a knock-
out allele termed 'FC' (Figure 1B). Both Mll2-/- and
Mll2FC/FC embryos show the same developmental lethal
phenotype [5]. We made ES cells from Mll2F/F; Rosa26-
CreERT2/+ blastocysts. 4-hydroxy tamoxifen induction
resulted in over 95% recombination by 24 hours (Figure
1C) and loss of Mll2 protein after 48 hours (Figure 1D).
To determine candidate Mll2 target genes in ES cells, we
harvested RNA for Affymetrix expression profiling before
and after 96 hours of tamoxifen induction to yield 'condi-
tional' samples (Figure 1E). For greater accuracy, we also
harvested RNA from our previously described double-tar-
geted Mll2-/- and FLP rescued ES cell lines [20] to yield
'constitutive' samples. A summary of expression changes
greater than ~1.7 fold (p values <0.0001) is shown in Fig-
ure 1E. The constitutively mutated cells showed a similar
number of up and down-regulated genes at this threshold
(34 and 31 respectively). However, the conditionally
mutated cells showed 10-fold greater down-regulated
genes than up (57 and 6, respectively), which is consistent
with expectations from the published roles of Mll2 as a
transcriptional activator and/or maintenance factor. Of
the six up-regulated genes in the conditional experiment,
four (Ly6a, Tbx3, 1700097N02Rik, 2210409E12Rik) were
also found amongst the 34 constitutively up-regulated
genes. In contrast to this discordance of up-regulated
genes, the two experimental approaches show signifi-
cantly better agreement for the down-regulated genes (Fig-
ure 1E). In addition to slightly different genetic
backgrounds for the two ES cell lines (129 versus mixed
129/C57Bl6), we suggest that the different results are due
to secondary adaptations in the constitutively mutated
cells. These cells were derived from a single cell after tar-
geting followed by more than 25 cell cycles in culture
before mRNA was harvested. In contrast, the condition-
ally mutagenized cells lost Mll2 within the previous 72
hours en masse and so the expression changes will more
directly reflect Mll2 action. Notably most of the down-reg-
ulated genes in the conditional experiment are expressed
from CpG island promoters (48/57), particularly in the
group that overlapped with the constitutive experiment
(23/24), which are most likely to be directly regulated by
Mll2.
Magoh2 is a direct target for Mll2
The 10 most down-regulated genes in common between
the two experimental approaches were evaluated by quan-
titative reverse transcriptase polyermase chain reaction
(RT-PCR) and good agreement to the microarray data was
found for all of them (Additional file 1). Given the pub-
lished roles of the H3K4 methyltransferases in transcrip-
tional activation and/or maintenance, we were surprised
to find very few genes down-regulated more than about
The Magoh2 promoter is a direct target for Mll2 and a model example of trxG/PcG opposition (part 1)Figure 2
The Magoh2 promoter is a direct target for Mll2 and a model example of trxG/PcG opposition (part 1). (A) Dia-
grams of the Magoh2 and Magoh genes, showing the exon structures, the positions of the CpG island promoters (as hatched 
lines around exon 1) and the PCR primer pairs for chromatin immunoprecipitation (ChIP) analysis. (B) Histogram of quantita-
tive RT-PCR analysis of Magoh (dark green) and Magoh2 (light green) mRNA levels before and after addition of 4-hydroxy 
tamoxifen to Mll2F/F; Rosa26-CreERT2/+ cells.
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Epigenetics & Chromatin 2009, 2:5 http://www.epigeneticsandchromatin.com/content/2/1/5twofold in absence of Mll2 and only one gene whose
expression completely relied upon Mll2. This gene is a
duplication of Magoh and was previously unnamed
(2010012C16Rik). Hence we call it Magoh2 (Figure 2;
Additional file 2). Befitting the role of Magoh as a house-
keeping function in mRNA export [21], both Magoh and
Magoh2 appear to be ubiquitously expressed in all tissues
examined (Additional file 2B).
After tamoxifen induction, Magoh2 mRNA levels fell (Fig-
ure 2B) in concordance with falling Mll2 protein levels
(Figure 1D), whereas Magoh mRNA levels were
unchanged. Similarly, Mll2 occupancy and H3K4me3 lev-
els fell at the Magoh2 but not Magoh promoter (Figure 3).
For technical reasons, the loss of Mll2 at the Magoh2 pro-
moter was difficult to detect. However, the loss of
H3K4me3 was greater than 20-fold, both immediately 5'
to, and within, its CpG island promoter.
We next looked for changes in the opposing histone
methylation marks at H3K27 and H3K9. Within the CpG
island of Magoh2, H3K27me3 levels increased more than
sixfold, whereas H3K9me3 levels did not change. Nota-
bly, H3K27me3 levels also went up slightly in the hetero-
The Magoh2 promoter is a direct target for Mll2 and a model example of trxG/PcG opposition (part 2)Figure 3
The Magoh2 promoter is a direct target for Mll2 and a model example of trxG/PcG opposition (part 2). ChIP 
analysis of the Magoh2 and Magoh promoters, as indicated at the top for the Magoh2 up, exon 1, down and Magoh exon 1 Q-
PCR primer pairs as diagrammed in (Figure 2A). The first row of panels shows ChIP results obtained from TAP-tagged Mll2 ES 
cells using the TAP tag for immunoprecipitation compared with 5% of the input before immunoprecipitation. Foldness of Mll2-
specific enrichment is noted at the side of each of the four panels. The second, third and fourth row of panels show fold change 
of chromatin immunoprecipitation using H3K4me3, H3K9me3 and H3K27me3-specific antibodies. Mll2F/F; Rosa26-CreERT2/+ 
(Mll2FC/FC)or Mll2F/+; Rosa26-CreERT2/+ (Mll2FC/+) cells were cultured for 12 days without (-) or with 4 days of 4-hydroxy 
tamoxifen for the last 4 days (d4), the middle 4 days (d8) or the first 4 days (d12).
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Epigenetics & Chromatin 2009, 2:5 http://www.epigeneticsandchromatin.com/content/2/1/5zygous control cells (Mll2F/+; Rosa26-CreERT2/+). This
suggests that the balance of H3K4me3 to H3K27me3
within the CpG island was also responsive to a 50%
reduction of Mll2 protein level. No other H3K27me3 (or
K9me3) changes were apparent, including immediately
outside of the CpG island on both 5' and 3' sides, even
though losses of H3K4me3 occurred on the 5' side.
As evaluated by bisulfite sequencing (Figure 4A), CpG
methylation-sensitive Southern blotting (Figure 4B and
4C) or PCR (Figure 4C), the Magoh2 promoter became
CpG methylated following the loss of Mll2 protein and
H3K4me3. These results show that Magoh2 requires Mll2
for expression in ES cells, in part due to the antagonism of
repression mediated via H3K27 and CpG methylations.
Mll2 is only required in a brief developmental window and 
not in adult mice
Though Mll2 is only required for a small amount of
mRNA expression in ES cells, an Mll2 knock-out was
lethal before E10.5 [5]. To investigate whether Mll2 is
required after E10.5, particularly for somatic homeostasis,
tamoxifen was used to induce Cre recombination in 2-
month-old adults. Although we could not induce efficient
recombination in the brain, recombination elsewhere was
nearly complete (Figure 5A and 5B). Unexpectedly we
found that adult mice lacking Mll2 appeared normal.
These mice showed only slight abnormalities, had normal
weight and blood profiles, lived as long as their litterma-
tes and were not prone to tumorigenesis or any other
notable pathology (data not shown). As ligand-induced
recombination will never be absolutely complete [15], we
checked old Mll2FC/FC; Rosa26-CreERT2/+ mice for
repopulation of various compartments with the unrecom-
bined allele, particularly in blood. No repopulation was
observed under any circumstance (data not shown), indi-
cating that Mll2 is dispensable for most somatic stem cells
and cell types.
In the course of these experiments, which include more
than 200 FC/FC mice so far, we discovered that tamoxifen
treatment of homozygous Rosa26-CreERT2 mice caused
death in more than half of the cases due to an intestinal
complication, which includes diarrhea, altered bile secre-
tion, stomach distension and an apparent loss of peristal-
sis (Additional file 3). This problem required tamoxifen
administration and homozygosity of Rosa26-CreERT2 but
not the Mll2 conditional (F) allele (either heterozygous or
homozygous). We avoided the problem by performing
tamoxifen inductions in Rosa26-CreERT2/+ heterozygotes.
To determine when Mll2 was required, we administered
tamoxifen to both pregnant and lactating mothers to
induce recombination in utero or in neonates, respec-
The Magoh2 promoter is a direct target for Mll2 and a model example of trxG/PcG opposition (part 3)Figure 4
The Magoh2 promoter is a direct target for Mll2 and a model example of trxG/PcG opposition (part 3). (A) 
Bisulfite sequencing results of the Magoh2 promoter before (-) and after (4-OHT) addition of tamoxifen for 4 days, followed by 
a further 8 days of culture shown below a diagram of the promoter, which illustrates the location of the CpG dinucleotides as 
well as the relevant restriction sites, Southern probe and PCR primers (small arrows either side of the Hpa1 sites) for the 
results shown in panels (B) and (C). (B) Southern blot to evaluate CpG methylation at the NaeI site of the Magoh2 promoter as 
illustrated in panel (A). Because the NaeI site contains two CpGs, resistance to restriction can reflect methylation at either or 
both sites, as illustrated at the right of the panel. The time course was performed on Mll2F/F; Rosa26-CreERT)/+ cells starting 
with addition of 4-hydroxy tamoxifen. (C) As for panel (B) except the genomic DNA samples were digested with HpaI before 
Q-PCR analysis with the primer pair illustrated in panel (A). These data are plotted (red circles, lower plot), as well as quanti-
tation of the Southern blot shown in panel (B; black circles, upper plot).
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Ligand-induced mutagenesis of Mll2 in utero, via lactation and in adultsFi ure 5
Ligand-induced mutagenesis of Mll2 in utero, via lactation and in adults. (A) Southern blot of tamoxifen-induced 
CreERT2 recombination in various tissues of a 2-month-old Mll2F/F; Rosa26-CreERT2/+ male two weeks after tamoxifen admin-
istration. The first lane shows tail DNA before tamoxifen administration with the 3.4 kb unrecombined band. All other lanes 
show DNAs after tamoxifen displaying the recombined 2.6 kb band. (B) Western blot of protein extracts from wild type and 
tamoxifen induced Mll2F/F; Rosa26-CreERT2/+ male testis and brain. The 300 kD protein, CBP, was used as a loading control. 
(C) Recombination efficiency in E10.5 embryos was detected by Southern blot. Pregnant mothers were untreated (-) or 
treated with one dose of 4 mg tamoxifen at E10 (12 h) or E8.5 (48 h). (D) The Mll2-/- phenotype was recapitulated in Mll2F/F; 
Rosa26-CreERT2/+ embryos after induction at E4.5 and E5.5 with doses of 1 mg tamoxifen. The embryos were harvested at 
E10.5. The inset shows a Mll2-/- embryo at E10.5 at the same scale. (E) Control Mll2F/+; Rosa26-CreERT2/+ embryos induced 
with tamoxifen at E4.5/E5.5 were normal at E10.5. (F, G) Mll2 is dispensable from E11.5. Mll2F/F; Rosa26-CreERT2/+ (F) and 
Mll2F/+; Rosa26-CreERT2/+ embryos (G) induced at E8.5 were normal at E12.5. (H) Southern blot of various tissues harvested 
from 14-day-old Mll2F/F; Rosa26-CreERT2/+ neonates, using the same strategy as in panel (A) and five daily doses of 4 mg 
tamoxifen to the lactating mothers, starting 4 days after delivery. (I) Body weight measurements after birth of Mll2F/F; Rosa26-
CreERT2/+ or Mll2F/+; Rosa26-CreERT2/+ pups treated with tamoxifen or not as in panel (H).
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Epigenetics & Chromatin 2009, 2:5 http://www.epigeneticsandchromatin.com/content/2/1/5tively. Recombination was induced in utero by administra-
tion of tamoxifen to pregnant Mll2F/F females after
crossing to Mll2F/F; Rosa26-CreERT2/Rosa26-CreERT2
homozygous males. For control litters, the same female
genotype was crossed with Mll2+/+; Rosa26-CreERT2/
Rosa26-CreERT2 homozygous males to produce Mll2F/+;
Rosa26-CreERT2/+ embryos. Pregnant females received
either two doses of 1 mg tamoxifen on two consecutive
days (E4.5/5.5; E8.5/9.5) or one dose of 4 mg (E8.5 and
later) by oral gavage. Recombination was virtually com-
plete in all mutant embryos within 48 hours (Figure 5C
and data not shown). Induction at E4.5/5.5 provoked the
same embryonic lethal phenotype observed in Mll2 null
embryos, namely pleiotropic growth and developmental
retardations with death before E10.5 (Figure 5D).
Tamoxifen administration at E8.5/9.5 showed no obvious
differences between Mll2FC/FC or Mll2FC/+ littermate
controls at E12 (Figure 5F and 5G). Pups induced at
E12.5/13.5, whether control or Mll2FC/FC, were normal
at birth but died due to poor fostering by the tamoxifen-
treated mothers, as apparent from failures to clean away
the placenta or to suckle and lactate. Untreated foster
mothers rescued both control and Mll2 deleted pups (data
not shown). Poor fostering was not observed when
tamoxifen was administered to the mothers after birth.
Five doses of 4 mg tamoxifen administered by gavage once
a day from P5 to P9 induced near-complete recombina-
tion in the pups, indicating that tamoxifen is efficiently
transmitted through the milk by suckling (Figure 5H). All
tamoxifen-treated pups were monitored for 6 weeks and
developed normally. Tamoxifen-induced recombination
in the neonatal brain was more efficient than in adults but
still incomplete. Whereas control pups not receiving
tamoxifen gained weight more rapidly than tamoxifen-
treated pups, there was little difference between Mll2FC/
FC and Mll2FC/+ pups (Figure 5I). This indicates that
tamoxifen administration has a minor effect on growth of
neonates, probably by reducing lactation of the mother
[22], while the absence of Mll2 does not. Taken together
with the results from tamoxifen treatment of 2-month-old
adults, we conclude that Mll2 is only essential before
E10.5 in development and is not required for further
development or somatic homeostasis. If loss of Mll2 pro-
tein in utero upon tamoxifen induction shows the same
kinetics as it does in ES cells (Figure 1D), we can narrow
this window to between E7.5 and E10.5.
Male mice lacking Mll2 are infertile
Although we did not find any somatic abnormalities after
tamoxifen treatment, Mll2FC/FC; Rosa26-CreERT2/+
males and females became infertile. To investigate the
male infertility, we established breeding experiments.
First, 11 male (Figure 6A and 6B) Mll2F/F; Rosa26-
CreERT2/+ (mutant) or mll2F/+; Rosa26-CreERT2/+ (con-
trol) mice were individually caged with two female wt
mice each. All mice gave successful fertilizations. The
males were then treated with tamoxifen followed by intro-
duction and weekly replacement of two wt females to
establish the time courses shown in Figure 6A and 6B.
Both control and mutants showed infertility in the first
and second weeks after tamoxifen treatment, followed by
recovery in the third and fourth weeks (Figure 6A). In the
control males, fertility was fully recovered by the fifth
week. However, recovery in the FC/FC males was transient
and complete infertility was observed after the sixth week.
Genotyping the offspring revealed that the mutant males
transmitted the unrecombined haplotype (Mll2F) in the
second and third weeks and the recombined haplotype
(Mll2FC) from the third to sixth weeks. As spermatogene-
sis in the mouse takes 5 weeks with 5 days of epididymal
transition (Figure 6B) these results permit the following
conclusions:
1. As loss of Mll2 did not prevent fertility between
weeks 3 and 6, male infertility is due to failures in
spermatogenesis and not because of the loss of other
abilities. This conclusion is supported by the observa-
tions that serum testosterone levels and plugging fre-
quencies were normal in Mll2FC/FC males (data not
shown).
2. As the unrecombined allele was transmitted in
weeks 2 and 3, recombination was inefficient in the
late stages of spermatogenesis (elongated spermatids
and maturing spermatozoa).
3. The transmission of both haplotypes (Mll2F and
Mll2FC) in the third week shows partial recombina-
tion in round spermatids.
4. Sole transmission of the recombined haplotype 4 to
6 weeks after tamoxifen treatment indicates that com-
plete recombination occurred in primary and second-
ary spermatocytes and spermatogonia.
5. Sterility in the sixth week after induction indicates
that the interruption of spermatogenesis occurred very
early during the spermatogonial stages.
Male infertility is caused by a block of spermatogenic 
differentiation
The mutant testes were obviously smaller after 2 months
(Figure 6C and 6D). Histological examination confirmed
the progressive germ cell loss inferred in Figure 6B. The
earliest visible abnormality was a dramatic reduction in
spermatocytes 2 weeks after induction (Figure 6F).
Whereas Sertoli and interstitial cells, spermatogonia and
preleptotene spermatocytes (stages VII–VIII) appearedPage 7 of 16
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Loss of Mll2 leads to male sterilityFigure 6
Loss of Mll2 leads to male sterility. (A) The fertility of 11 control (black) or mutant males (grey) was tested by weekly 
breedings to two wild-type females before and after tamoxifen administration. The mutants initially transmitted the unrecom-
bined haplotype (light grey), and then the recombined haplotype (dark grey) and lost fertility by week 7. (B) The diagram illus-
trates a spermatogenic period of 40 days with mitosis (red), meiosis I (orange), meiosis II (yellow), spermiogenesis (green) and 
spermatozoa maturation (blue). Indicated are spermatogonia (SG), leptotene spermatocytes (LS), pachytene spematocytes 
(PS), rounded spermatids (RS) and elongated spermatids (ES). The transmission of the unrecombined haplotype (light grey) 
indicates that recombination did not occur in ES and only partially occurred in RS. Although recombination was complete in LS 
and PS, spermatogenesis proceeded (dark grey). Permanent sterility occurring in the sixth week indicated that spermatogenesis 
was interrupted before or at meiosis I (red line) (C, D) Wild-type, control and atrophic mutant testes 8 weeks after tamoxifen 
induction (C) or weighed during a time course (D). (E to J) Testis histological cross-sections reveal a block of germ cell differ-
entiation and progressive loss of spermatogonia in Mll2FC/FC testis. Control testis (E) were normal after tamoxifen treatment. 
Mutant testis were sectioned 1 week (F), 2 weeks (G), 3 weeks (H), 4 weeks (I) and 14 weeks (J) after induction. (K, L) 
Increased levels of spermatogonial apoptosis in Mll2FC/FC testis, determined by TUNEL staining in control (K) and mutant (L) 
testis sections 3 weeks after tamoxifen induction. (M, N) Persistence of Tra98-positive cells 4 months after tamoxifen induc-
tion. Double staining with a Tra98 antibody and DAPI shows the expected distribution of Tra98 in control testis (M) and 
reduced staining in mutant testis (N). (O, P) Expression of Mll2 (O) and Mll (P) in normal testis detected by in situ hybridization 
with antisense probes.
Epigenetics & Chromatin 2009, 2:5 http://www.epigeneticsandchromatin.com/content/2/1/5normal, we observed reduced frequencies of leptotene/
zygotene spermatocytes (stages IX–XII) and early pach-
ytene spermatocytes (stages I–IV). These observations,
together with the absence of degenerating spermatocytes,
indicated a developmental block in spermatogenic differ-
entiation before the early pachytene stage. Three weeks
after tamoxifen induction, the tubules contained sperma-
togonia, preleptotene spermatocytes and spermatids but
no pachytene spermatocytes (Figure 6G). In addition to
the immediate arrest of germ cell differentiation we also
observed a progressive depletion of spermatogonia at later
stages (Figure 6H to 6J). Increased apoptosis of spermato-
gonia was detected from 1 week after induction and
peaked around 3 weeks (Figure 6K and 6L). Staining for
Tra98 4 months after tamoxifen induction showed the
presence of Tra98-positive cells, indicating that some sper-
matogonia persisted (Figure 6M and 6N).
These observations indicate one or two primary defects in
Mll2FC/FC testes: (i) a developmental block in sperma-
togenic differentiation before the pachytene stage; (ii) a
defect in the production of spermatogonial B cells from A
cells.
The Mll2 expression pattern in testes concords with a role
for Mll2 in spermatogonia because in situ hybridization
revealed strong expression in these cells, but weak or
absent expression in spermatocytes, Sertoli and Leydig
cells (Figure 6O). Interestingly, we observed a comple-
mentary Mll expression pattern with strong signals in
spermatocytes and Leydig cells, and a weak or absent sig-
nal in spermatogonia (Figure 6P).
Molecular characterization of Mll2FC/FC testes
Quantitative RT-PCR analysis on total testis RNA at sev-
eral time points after tamoxifen induction (1, 2, 3, 4 and
8 weeks) was used to characterize alterations in gene
expression (Figure 7). As a first control, we compared gene
expression in uninduced control males with control males
1 week after tamoxifen treatment. No significant differ-
ences were detected, indicating that tamoxifen did not
influence expression of these genes (Figure 7). As a second
control, RNA was also harvested from testes treated with
busulfan, which clears the germ lineage leaving only Ser-
toli and Leydig cells. As markers for spermatogonia, we
examined expression of Plzf, C-kit and Stra8 [23-25].
Expression of these genes persisted, which concords with
the observed persistence of Tra98-positive cells (Figure
6N). In contrast, Oct4, which is normally co-expressed
with Plzf in undifferentiated spermatogonia [26], was
strongly reduced 3 weeks after induction, suggesting a
gene-specific effect of Mll2 mutagenesis.
Next we tested genes that are expressed in spermatocytes
at prepachytene (Bmp8, Sycp3) and pachytene (CcnA1,
Calmegin) stages [27]. These genes all showed decreased
expression over the time course in agreement with the
increasing depletion of post-spermatogonial stages seen
in the histology. Whereas CcnA1 and Calmegin expression
disappeared rapidly, Sycp3 and Bmp8 expression initially
decreased but persisted for several weeks before com-
pletely disappearing. This indicates that pachytene sper-
matocytes were rapidly lost, while some leptotene and
zygotene spermatocytes persisted. We also looked at a
panel of Sertoli-specific genes, which showed continued
expression as expected, except for rhox3 and rhox11 (Addi-
tional file 4A). Notably both of these genes were also
depleted by busulfan treatment, suggesting that their
expression is dependent upon signals received by the Ser-
toli cells from spermatogenesis.
To identify genes with altered expression after loss of Mll2
but before the cellular composition of the mutant testis
was affected, expression profiling was performed by
microarray analysis from testes 6 days after tamoxifen
induction (Additional file 4C). Major candidates were ver-
ified by quantitative RT-PCR, including the candidate
with the most reduced expression, Kctd14, and two candi-
dates that were dramatically up-regulated, Cap1 and Vav2
(Figure 7). We also evaluated testis expression of three
Mll2 target genes identified in ES cells, namely Magoh2,
Ddx4 and Dazl. Ddx4 expression in testis was lost with
similar kinetics as Oct4, suggesting a loss of expression in
spermatogonia. Dazl and Magoh2 showed a twofold
reduction in expression (Figure 7). For Dazl, sustained
expression in testis obviously does not require Mll2 and is
concordant with the persistence of spermatogonia A [28].
For Magoh2, the twofold reduced expression in testis upon
loss of Mll2 stands in stark contrast with the complete reli-
ance on Mll2 observed in ES cells (Figures 2, 3 and 4).
Discussion
Epigenetics was first conceived as a necessary mechanism
for multi-cellular organisms to use a single genome in
multiple ways [4,13]. Roles for epigenetic mechanisms in
transcriptional regulation, defining or confining cellular
identity and maintaining homeostasis follow from this
concept. The work described here started with the inten-
tion to look for epigenetic roles in the maintenance of cel-
lular identity by use of conditional mutagenesis to remove
an H3K4 methyltransferase, Mll2, from somatic states.
Unexpectedly, we found that many cellular identities are
apparently indifferent to the removal of Mll2. However,
Mll2 is required during a developmental window and in
both male and female germ lineages. We discuss the
implications of these findings in turn.
Redundancy of mammalian H3K4 methyltransferases
Mammals have at least six H3K4 methyltransferases in
three pairs of sister genes [5]. Consequently functionalPage 9 of 16
(page number not for citation purposes)
Epigenetics & Chromatin 2009, 2:5 http://www.epigeneticsandchromatin.com/content/2/1/5redundancy, or overlapping functional plasticity and
compensation, is plausible. Nevertheless, because Mll2 is
essential during development, we did not expect it to be
thoroughly dispensable in adult mice (except possibly in
the brain, which we could not evaluate because
tamoxifen-induced recombination was incomplete). Pre-
viously we established that Mll2 could be removed from
ES cells by gene targeting of both alleles. However, a
number of defects were observed, including an increased
level of apoptosis due to decreased Bcl2 expression and a
strongly decreased ability to differentiate towards the neu-
ral lineages [20]. Hence significant somatic perturbations
were expected in the adult mouse upon removal of Mll2.
In contrast, our extensive investigations have only
revealed subtle somatic effects so far (SG, AK, unpub-
lished observations).
Removal of Mll2 by conditional mutagenesis in ES cells
permitted an accurate appraisal of changes in mRNA lev-
els and also revealed only subtle alterations. Only one
gene, Magoh2, was found to rely entirely on Mll2 for
expression and only a few were altered more than two-
Expression analysis by quantitative RT-PCR of selected genes in mll2 mutant and control testesFigure 7
Expression analysis by quantitative RT-PCR of selected genes in mll2 mutant and control testes. The expression 
levels from total testes of controls (black) before (-) or 1 week after tamoxifen were compared with mutants (grey) after 
tamoxifen administration. All times refer to weeks after the start of five daily doses of 4 mg tamoxifen. Busulfan-treated testes 
were used to generate Sertoli-cell only controls (SCO). All data is based on at least three mice. The mean value ± SEM of rel-
ative expression normalized against the endogenous standard genes GAPDH and Rpl19 is shown (* P < 0.05; ** P < 0.02).
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cell phenotype, we think that mRNA profiling has been
insufficient and other circuitry, such as microRNA expres-
sion, should be evaluated.
Regulation of Magoh2 by Mll2 is an illuminating case
study. Like all validated Mll2 target genes, Magoh2 is
expressed from a CpG island promoter. Mll2 and its sister,
Mll, contain the CxxC protein domain, which binds
unmethylated CpGs [29-31]. This domain is also present
in Cfp1, which is a subunit of the mammalian Set1A and
Set1B H3K4 methyltransferase complexes [32,33]. As
unmethylated CpGs are normally only found in CpG
islands [34,35], potentially the CxxC domain localizes
these four H3K4 methyltransferases to CpG island pro-
moters. For technical reasons, we have been unable to
explore this proposition by global ChIP, either using Mll
or Mll2-specific antibodies, or Mll and Mll2-tagged pro-
teins. However a ChIP-on-chip analysis in U937 cells for
Mll found an almost complete concordance of Mll ChIP
with Pol II and active genes [36], which could reflect a
level of redundancy within the H3K4me3 system whereby
any H3K4me3 promoter, once established, will recruit
one or more of the other six H3K4 methyltransferases,
potentially via PHD fingers either within the enzymes
themselves (for Mll1–4) or the complex Cfp1/Spp1 (for
the Set1A and B complexes; [37]). Hence, it may be diffi-
cult to establish the non-redundant relationships between
promoters and H3K4 methyltransferases.
In ES cells, expression of Magoh2 collapses upon removal
of Mll2. Loss of Mll2 is accompanied by loss of H3K4me3
but also gain of H3K27me3 at the Magoh2 promoter.
Hence the Trithorax orthologue, Mll2, is required to
oppose repression mediated, in part, by a Polycomb-
Group mechanism. This example concords with the oppo-
sition between trx-G and Pc-G action as elucidated in flies
[1,38]. Furthermore, we observe that CpG methylation
adds an extra level of repression to Pc-G repression with-
out the apparent involvement of H3K9 methylation.
Hence, as known for X-chromosomal inactivation [39],
Pc-G repression can be accompanied by CpG methylation
also on an autosomal gene. This has important implica-
tions for the epigenetic causes of tumorigenesis, which
have hitherto focused on the acquisition of tumor sup-
pressor gene silencing [40]. We suggest that mechanisms
which provoke loss of trx-G maintenance of tumor sup-
pressor gene expression should also be examined care-
fully.
Mll2 is only required during a brief developmental window
Conditional mutagenesis allowed us to identify the
period in which Mll2 is essential. This period encom-
passes gastrulation and early organogenesis. Two ques-
tions arise. Why is Mll2 essential during this period? And
why is it not essential at other times? To answer these
questions, we propose the following bimodal explana-
tion, which we call the 'recruit and maintain' (RAM)
model. First, in almost all cellular states, Mll2 is part of an
implicitly redundant or overlapping mechanism(s),
which includes one or more of the other H3K4 methyl-
transferases (Mll, Set1A, Set1B, Mll3, Mll4). Second, dur-
ing lineage commitment in gastrulation and
organogenesis, new patterns of gene expression are estab-
lished, which include the lineage-specific selection of cer-
tain genes to be epigenetically maintained in the active
state. Third, the selection of these genes includes the
recruitment of trx-G components, such as a H3K4 methyl-
transferase. Fourth, in certain cases, only one of the H3K4
methyltransferases is recruited and in its absence, none of
the others substitute. Fifth, once recruited, the implicitly
redundant or overlapping mechanism is established and
propagates the activity of the promoter (Figure 8).
Above we pointed out the potential relationship between
Mll, Mll2 and CpG island promoters. Virtually all house-
keeping genes are expressed from CpG island promoters.
However, in contrast to the understanding of TATA box
promoters, the understanding of CpG island promoters is
thin [41]. We suggest that the underlying basis for the
activity of housekeeping promoters in all cells is epige-
netic, based in part on an inheritable mechanism involv-
ing H3K4me3, Mll1, Mll2, Set1A and Set1B. Furthermore,
we suggest that this constitutive cellular mechanism is
selectively recruited to certain genes during lineage com-
mitment to convey inheritable (epigenetic) activation in a
lineage-specific pattern. Or stated more plainly, these cer-
tain genes become like 'housekeeping' genes for the pur-
pose of the specific lineage.
The RAM model offers an explanation for the lack of a
major phenotype in conditionally mutated Mll mice.
Using a Vav-Cre line for conditional mutagenesis that
ablated Mll expression in the liver and blood lineages,
McMahon et al [7] bypassed the embryonic lethality of
Mll knock-outs to show that Mll could be removed from
these cell types during late development and in the adult
without notable impact. Although this analysis was con-
fined to a few cell types, it does concord with the findings
we report here for Mll2 and the RAM model.
Notably the Magoh2 promoter in ES cells appears to be an
exception to the RAM model. It is difficult to explain why
the Magoh2 promoter in ES cells relies solely on Mll2 and
cannot be supported by any of the other H3K4 methyl-
transferases. This suggests that other determinants in addi-
tion to CpG dinucleotides and H3K4me3 are involved in
defining CpG island promoters. Alternatively, this may be
another unusual aspect of ES cell chromatin [42]. Nota-
bly, Magoh2 does not rely on Mll2 in testis (Figure 7).Page 11 of 16
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Both male and female germ lineages require Mll2 at a spe-
cific stage, which is likely to be shortly before meiosis in
both cases. Loss of Mll2 does not prevent primordial germ
cell migration into the genital ridge (SG, AK unpublished
observations). The nature of the female germ line defect
will be the subject of a different paper. Here we estab-
lished that the defect in the male germ line occurs
between spermatogonia A and the pre-meiotic pachytene
spermatocyte stages, resulting in apoptosis and conse-
quently a complete loss of spermatogenic cells. However,
the persistence of the spermatogonia A stem cells, as
shown by the persistence in mutant testis of various defin-
ing mRNAs and Tra98-positive cells, indicates that the
defect occurs upon exit from the stem cell state. Although
more work needs to be done to define the nature of this
defect, we suggest that it also concords with the RAM
model. Namely, Mll2 is not required to maintain the sper-
matonial stem cell but is required upon exit from the stem
cell state, presumably due to changes in gene expression.
Spermatogenesis may be idiosyncratically susceptible to
the loss of Mll2 because Mll is not sufficiently co-
expressed in the spermatogonia (Figure 6P). Notably, our
data indicate that removal of Mll2 does not eliminate
spermatogonia A; rather, the defect is revealed in the com-
mitted daughter cells.
Mll2 target genes
Ddx4 and Dazl were both high on the list of down-regu-
lated genes from the ES cell expression profiling. Along
with Magoh2, the fly homologues of these three proteins
are involved in germ cell granules in the germ line [43-
45], and loss of either Ddx4 (also called Mouse vasa
homologue) and Dazl (deleted in azoospermia), causes
male sterility in mice [27,28]. Therefore potentially Mll2
regulation underpins an evolutionarily conserved germ
cell program.
Although we did not observe any gene ontology linkages
among the candidate Mll2 target genes, a strong correla-
tion with CpG island promoters was observed. So far, 23
of the top 24 Mll2 candidate target genes identified in ES
cells have CpG islands (Figure 1; Additional file 1). At the
threshold used, approximately 60% of all mouse promot-
ers are CpG islands. As the chance that 23 of 24 are CpG
islands at this threshold is less than 1E-7, we find support
for a relationship between Mll2 and CpG islands.
Conditional mutagenesis
Conditional mutagenesis in the mouse has proven to be
remarkably powerful since its first application [46] and
the addition of ligand regulation [15-17,47-49] has fur-
ther increased its precision. However, it is not without its
problems [50-53] to which we add another one (Addi-
tional file 3). Nevertheless, when applied carefully the
value of these tools greatly outweighs their deficiencies,
which emphasizes the need to design experiments with
the proper controls. Here we used the heterozygously
floxed allele as the control for the homozygously floxed
experiment. In both cases, the Rosa26-CreERT2 allele was
heterozygously present and tamoxifen induction caused
the same Cre recombination either heterozygously for the
control or homozygously for the conditional mutation.
Ligand-induced recombination added temporal control
to conditional mutagenesis. Its first useful applications in
mice were based on a combination of temporal and spa-
tial regulation [47-49]. Here we applied it solely for tem-
poral regulation using expression from the Rosa26 locus.
The absence of background recombination before induc-
tion, and the rapid and near ubiquitous recombination
after induction, demonstrate the good properties of this
The recruit and maintain (RAM) model to explain the tran-sient req rement for Mll2Figu  8
The recruit and maintain (RAM) model to explain 
the transient requirement for Mll2. The diagram illus-
trates two nucleosomes at a gene promoter, to which Mll2 is 
recruited. Once recruited, Mll2 mediates the establishment 
of a back-up system, partly via H3K4 trimethylation, which is 
based on its sister, Mll, and potentially the other H3K4 meth-
yltransferase pairs, Set1A/Set1B and Mll3/Mll4. The epitopes, 
x and y, are included to indicate that other chromatin deter-
minants are likely to play roles in recruitment and mainte-
nance.
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recombination in the brain. We believe this is due to the
weak, but not absent, expression from the Rosa26 pro-
moter in post-mitotic neurons [54], rather than the inabil-
ity of tamoxifen to cross the blood-brain barrier.
Conclusion
The studies reported here began with the intention to
examine epigenetic mechanisms in the maintenance of
cellular identities using conditional mutagenesis of Mll2
as the model case. Unexpectedly we found that Mll2 is
only required briefly in certain conditions. During devel-
opment it is not required in the pluripotent stem cells but
at certain points around gastrulation. During sperma-
togenesis, it is not required in spermatogonia A stem cells
but in the differentiating spermatogonia. We therefore
propose a model whereby Mll2 function is only occasion-
ally essential during alterations of cellular gene expression
programs and otherwise is supported on established pro-
moters by a redundant mechanism(s). Furthermore, we
find a correlation between Mll2 target genes and CpG
island promoters and report a case where Mll2 is required
to prevent PcG repression of a CpG island promoter. PcG
repression is further secured by DNA methylation.
Methods
ES cells
Methods with ES cells have been described elsewhere
[20,55]. In addition, Mll2F/F; Rosa26-CreERT2/+ and
Mll2F/+; Rosa26-CreERT2/+ ES cell lines were isolated
from blastocyst outgrowths. Cre-mediated recombination
was induced by 10-6 M 4-hydroxy tamoxifen from 10-4 M
ethanol stocks.
Affymetrix gene chip analyses were performed with mouse
Set430_A arrays for the constitutive experiment or mouse
Set430_2.0 arrays for the conditional experiment. The
constitutive experiments were performed in triplicate
whereas the conditional experiments were performed in
quintuplicate. Conditional Mll2 ES cells were grown with-
out feeders on 0.1% gelatine-coated plates, induced for 48
h or not and harvested 96 h after the start of induction.
RNA extraction and processing were according to the
manufacturers' instructions. Statistical analyses of gene
expression profiles were performed with students t-test
ANOVA. Wild-type and FLP-rescued ES cell gene expres-
sion data were paired and compared with constitutive
Mll2-/- data. Probe sets with a statistical significance (p-
value) lower than E-04 were used for analysis. Microarray
data of conditional ES cells were analyzed by pairwise
comparison of genes with p-values lower than E-05 in a
students t-test ANOVA.
Chromatin immunoprecipitation with H3-K4me3, H3-
K27me3 (Abcam) and H3-K9me3-specific antibodies
(Upstate) used conditional Mll2F/F; Rosa26-CreERT2/+ ES
cells after induction with 4-hydroxy tamoxifen for 48 h
and crosslinked at day 4, day 8 and day 12. Uninduced ES
cells as well as tamoxifen-induced Mll2F/+; Roasa26-
CreERT2/+ ES cells were used as controls. Immunoprecip-
itations were carried out as described [56] and analyzed
by quantitative PCR analysis.
Primer pairs for bisulfite sequencing were Magoh2_BiS
and Magoh2_BiSnested. For Southern blot analysis, a 550
bp genomic probe for the Magoh2 promoter was gener-
ated by PCR amplification with the primer pair
Magoh2_probe. Genomic DNA of tamoxifen-treated or
untreated conditional Mll2F/F ES cells was digested with
EcoRI, BclI and methylation-sensitive NaeI. Methylated
CpG dinucleotides at positions +32 and/or +35 produced
a 1.8 kb fragment with NaeI-digested DNA samples, while
a 1.2 kb fragment was detected as long as both sites were
unmethylated. Methylation at two CpG dinucleotides
(positions -48 and -30) overlapping with two HpaII
restriction sites was detected by quantitative PCR with
primer pair Magoh2_HpaII. Genomic DNA of tamoxifen-
treated or untreated conditional Mll2F/F ES cells was frag-
mented with RsaI, which does not cleave between the
primer pair and therefore determined the Ct value of the
assay corresponding to uncleaved template. RsaI/HpaII-
digested DNA was used to determine the amount of
uncleaved template corresponding to methylation at both
CpG dinucleotides. RsaI/MspI-digested DNA served as
negative control and did not produce a PCR product
(primers listed in Additional file 5).
Mice
The Mll2-/- mice, genotyping and Western methods were
described previously [5]. Homozygous Mll2+/- were
crossed to hACTB-Flpe mice to generate Mll2F/+. Inter-
crosses of Mll2F/+ mice produced homozygous mll2F/F
mice at the expected Mendelian ratio, which were crossed
to the Rosa26-CreERT2 line. An NlaIII fragment of Mll2
cDNA (321 to 988) was used as probe that hybridized to
3.4 kb or 2.6 kb bands for Mll2F and Mll2FC respectively.
For in vivo tamoxifen inductions, tamoxifen base (Sigma,
T5648) was dissolved in peanut oil (Sigma) at 80 mg/ml.
The solution was shaken rigorously at 55°C until the
tamoxifen was completely dissolved and divided into 50
μl aliquots for storage at -20°C. Mice received one aliquot
containing 4 mg tamoxifen per day for five consecutive
days. Aliquots were heated at 37°C and given by gavage
with a 1.2 mm × 40 mm feeding needle (037-0129
MediQuick).Page 13 of 16
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drated in a graded ethanol series, and embedded in paraf-
fin. Mounted sections where used for hematoxylin/eosin
stainings, for immunohistochemical staining, and TUNEL
assays. For immunohistochemistry, antigen retrieval was
performed in 50 mM glycine (ph 3.5; 90°C maintained
for 8 min). TUNEL assays were performed on sections
treated with Proteinase K (10 μg/ml) for 15 min at 37°C
using the In situ Death Detection Kit (Roche). In situ
hybridization was performed with digoxigenin-labeled
cRNA probes (Mll, bp 11897 to 12400 of Accession no.
NM001081049; Mll2, bp 8151 to 8458 of Accession no.
NM029274) as previously described [57]. Total RNA from
testes were isolated using TriReagent (Sigma), pretreated
with Dnase I (Promega) and reverse-transcribed with
oligo-dT primers and Superscript III (Invitrogen). DNA
samples from at least three individual mice for each time
point after induction were analyzed by the SYBR green
method using a Stratagene MX4000. All assays produced
Ct values below 30 (Additional file 4B) and were normal-
ized against levels of GAPDH and Rpl19 mRNAs (all
primers are listed in Additional file 5).
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